Drug Profile
HL 10
Latest Information Update: 15 Jun 2004
Price :
$50
*
At a glance
- Originator Erasmus University; Friedrich-Alexander-University Erlangen-Nuremberg; HALAS Pharma
- Developer LEO Pharma
- Class Phospholipids; Pulmonary surfactants
- Mechanism of Action Cell membrane permeability enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Acute lung injury; Adult respiratory distress syndrome
Most Recent Events
- 08 Jun 2004 Discontinued - Phase-III for Acute lung injury in European Union (Intratracheal)
- 08 Jun 2004 Discontinued - Phase-III for Adult respiratory distress syndrome in European Union (Intratracheal)
- 13 May 2003 LEO Pharma is seeking a partner for the marketing of HL 10 in the USA and Japan (http://www.leo-pharma.com)